Bavituximab: Additional Phase IIb data

Peregrine said an internal review determined that the previously-announced discrepancies in data from a Phase IIb trial were isolated to the placebo and 1 mg/kg bavituximab plus docetaxel treatment arms and did

Read the full 324 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE